UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

## NOTICE OF ALLOWANCE AND FEE(S) DUE

210

7590

04/03/2008

MERCK AND CO., INC P O BOX 2000 RAHWAY, NJ 07065-0907 EXAMINER

COPPINS, JANET L

ART UNIT PAPER NUMBER

1626

DATE MAILED: 04/03/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560.672	12/14/2005	Christopher Bayly	MC085YP	2331

TITLE OF INVENTION: CATHEPSIN CYSTEINE PROTEASE INHIBITORS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$300	\$0	\$1740	07/03/2008

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

#### PART B - FEE(S) TRANSMITTAL

### Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450 (571)-273-2885 or <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for

maintenance fee notifications. Note: A certificate of mailing can only be used for domestic mailings of the CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 210 7590 04/03/2008 Certificate of Mailing or Transmission MERCK AND CO., INC I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. POBOX 2000 RAHWAY, NJ 07065-0907 (Depositor's name (Signature (Date APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/560,672 12/14/2005 Christopher Bayly MC085YP 2331 TITLE OF INVENTION: CATHEPSIN CYSTEINE PROTEASE INHIBITORS APPLN. TYPE SMALL ENTITY ISSUE FEE DUE PUBLICATION FEE DUE PREV. PAID ISSUE FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1440 \$300 \$0 \$1740 07/03/2008 **EXAMINER** ART UNIT CLASS-SUBCLASS COPPINS, JANET L 1626 514-329000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. or agents OR, alternatively, (2) the name of a single firm (having as a member a ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) 4a. The following fee(s) are submitted: lssue Fee A check is enclosed. Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number \_\_\_\_\_\_ (enclose an extra copy of this fo Advance Order - # of Copies \_ (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ■ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Date Typed or printed name Registration No. This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,672 12/14/2005		Christopher Bayly	MC085YP	2331
210 75	590 04/03/2008		EXAM	INER
MERCK AND C	MERCK AND CO., INC		COPPINS, JANET L	
P O BOX 2000			ART UNIT	PAPER NUMBER
RAHWAY, NJ 07065-0907			1626	
			DATE MAILED: 04/03/200	8

## **Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)**

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

	Application No.	Applicant(s)		
	10/560,672	BAYLY ET AL.		
Notice of Allowability	Examiner	Art Unit		
	JANET L. COPPINS	1626		
	JANET L. COPPINS	1020		
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject t	plication. If not included n will be mailed in due course. <b>THIS</b>		
1. 🔀 This communication is responsive to Applicants' Amendme	ent and Response of March 17, 200	<u>8</u> .		
2.   ☐ The allowed claim(s) is/are 1 and 3-8.				
3. Acknowledgment is made of a claim for foreign priority ur	nder 35 U.S.C. § 119(a)-(d) or (f).			
a) ☑ All b) ☐ Some* c) ☐ None of the:				
1. Certified copies of the priority documents have	e been received.			
2.  Certified copies of the priority documents have	e been received in Application No			
3. Copies of the certified copies of the priority do	cuments have been received in this	national stage application from the		
International Bureau (PCT Rule 17.2(a)).				
* Certified copies not received:				
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements		
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give				
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.				
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached				
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date				
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date				
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t				
6. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATERIAL	must be submitted. Note the		
Attachment(s) 1. ☑ Notice of References Cited (PTO-892)	5. ☐ Notice of Informal F	Patent Application		
<ol> <li>Notice of References Cited (PTO-092)</li> <li>Dotice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>	6. ☐ Interview Summary			
	Paper No./Mail Da	ite		
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. 🛛 Examiner's Amend	ment/Comment		
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Statem	ent of Reasons for Allowance		
Ŭ	9.			

Application/Control Number: 10/560,672 Page 2

Art Unit: 1626

#### **DETAILED ACTION**

1. Claims 1 and 3-8 are now pending in the instant application.

# Response to Amendment

2. Applicants' Amendment and Response to the Notice of Non-Compliant Amendment, submitted March 17, 2008, has been reviewed by the Examiner and entered of record in the file. Accordingly, claims 2 and 9-11 have been cancelled, claims 1 and 7 have been amended.

#### Oath/Declaration

3. In the previous Office Action, Examiner Cheng had indicated that a new Oath/
Declaration was required. Applicant's substitute Declaration, submitted March 17, 2008, has been accepted and entered of record in the file.

### Specification

4. The disclosure was previously objected to for containing informalities in pages 24-25, 42 and 45 of the specification. Applicants have submitted replacement paragraphs in order to correct the errors in the specification. Therefore, the objections are withdrawn.

### Previous Claim Rejections - 35 USC § 112

- 5. In the previous Office Action, Examiner Cheng had rejected claims 1-6, 8 and 10 under 35 USC 112, first paragraph, as not being enabled. In view of Applicants' amendatory changes to the claims, the rejections are withdrawn.
- 6. Claims 1-8 and 10 were previously rejected under 35 USC 112, second paragraph, as being indefinite. In view of the deletion of "N-oxides" from the claims, the rejections have been obviated and are withdrawn.

### Previous Claim Rejections - 35 USC § 102

Application/Control Number: 10/560,672 Page 3

Art Unit: 1626

7. Claims 1, 2, 4, 8 and 10 were previously rejected under 35 USC 102(b) as being anticipated by Bekkali et al and by Bailey et al. In view of Applicants' amendments in order to delete the overlapping subject matter from the claims, the rejections are withdrawn.

#### **EXAMINER'S AMENDMENT**

- 8. Claims 3 and 4 depend from cancelled claim 2.
- 9. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Nicole M. Beeler on March 31, 2008. The application has been amended as follows:

- a) Claim 3, please change the dependency from "Claim 2" to "Claim 1".
- b) Claim 4, please change the dependency from "Claim 2" to "Claim 1".

#### REASONS FOR ALLOWANCE

10. In view of Applicant's amendatory changes and cancellations, claims 1 and 3-8 are allowable over the prior art, as newly renumbered claims 1-7. The following is an examiner's statement of reasons for allowance:

This invention relates to novel cycloalkyl-carboxamide cyanomethyl compounds and their pharmaceutical compositions. The allowable compounds are limited to compounds according to the formula of claim 1, that are cysteine protease inhibitors. Certain carboxamide cyanomethyl compounds are known in the art as having pharmaceutical activity, however the aspect of preparing the instant claimed cycloalkyl-carboxamide cyanomethyl derivatives, with

inhibitory activity on cathepsins is novel and unobvious. The instant compounds were tested for selective inhibition of cathepsins K, L, B and S (please refer to inhibitory results, etc. found in pages 57 and 58 of the specification. After a thorough search, the closest of prior art, U.S. Pat. No. 6,313,117 to Bekkali, et al. was found to teach similar carboxamide-cyanomethyl derivatives. However the '117 patent fails to teach or render obvious the instant compounds according to the same formula of claim 1, and does not fairly suggest their pharmaceutical compositions.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

#### Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JANET L. COPPINS whose telephone number is (571)272-0680. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on 571.272.0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/560,672 Page 5

Art Unit: 1626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Janet L. Coppins

/Kamal A. Saeed/ Primary Examiner, Art Unit 1626